Dry eye disease (DED) is a clinically significant multifactorial disorder of the ocular surface and tear film as it results in ocular discomfort and visual impairment and predisposes the cornea to infections. It is important for the quality of life and tends to be a chronic disease. It is also common, as the prevalence is estimated between 5 % to 30 % and this increases with age. Therefore, it is recognised as a growing public health problem that requires correct diagnosis and appropriate treatment. There are two main categories of DED: the deficiency of tear production (hyposecretive), which includes Sjögren syndrome, idiopathic or secondary to connective tissue diseases (e.g. rheumatoid arthritis), and non-Sjögren syndrome (e.g. age-related); and the tear evaporation category, where tears evaporate from the ocular surface too rapidly due to intrinsic causes (e.g. meibomian gland disease or eyelid aperture disorders) or extrinsic causes (e.g. vitamin A deficiency, contact lenses wear, ocular allergies). Management of the disease aims to enhance the corneal healing and reduce patient's discomfort. This is based on improving the balance of tear production and evaporation by increasing the tear film volume (lubrication drops) and improving quality of tear film (ex omega-3 supplements, lid hygiene, tetracyclines), reducing the tear film evaporation (paraffin ointments, therapeutic contact lenses), reducing tear's drainage (punctal plugs, cautery) and finally by settling down the ocular surface inflammation (steroids, cyclosporine, autologous serous), as appropriate. In this article we will review the clinical presentation, differential diagnosis and treatment options for DED.
There is now an increased recognition by clinicians that dry eye disease (DED) is a common disorder characterised by dryness and damage of the ocular surface. It affects quality of life, including aspects of physical, social and psychological functioning, because it induces ocular discomfort, burning sensation, light sensitivity, visual disturbances or even corneal erosions and infections. DED is also known as keratoconjunctivitis sicca, dry eye syndrome and dysfunctional tear syndrome. DED prevalence has been reported to range from 5 % to 30 %, this being a likely result from differing study populations and DED definitions. In a large population study, Moss et al. reported the prevalence of dry eye to be 14.4 % in 3,722 subjects aged 48 to 91 years and noted that the prevalence of the condition doubled after the age of 59. As a consequence, DED prevalence is expected to increase in ageing populations, which will eventually make this health problem more prominent. [1] [2] [3] [4] In order to address the problem, the International Dry Eye Workshop (DEWS) defines dry eye as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. [3] [4] [5] Indeed, DEWS has recognised dry eye as a disturbance of the lacrimal functional unit, an integrated system comprising the lacrimal glands, ocular surface (cornea, conjunctiva and meibomian glands) and lids, and the sensory and motor nerves that innervate them. 3, 4 Dysfunction of any component of the lacrimal functional unit may lead to ocular surface disease, related to inflammation and increased tear film osmolarity.
This multifactorial aetiopathogenesis explains why the clinical diagnosis of dry eye remains a challenge, not only due to the wide spectrum of alterations of the ocular surface with different aetiology and pathophysiology, 5 but also due to the lack of well standardised diagnostic tests, 6 and the fact that corneal surface is sensitive to external stimuli and, while the most diagnostic tests are overly invasive, the non-invasive tests are still considered expensive for everyday practice. Therefore, a holistic approach and a careful examination of tear film, cornea, eyelids, anatomically and functionally, as well as a thorough clinical history is needed to diagnose DED. 3, [5] [6] [7] [8] Early diagnosis of DED and identification of the underlying cause is essential not only for the management of the ocular surface disease, but also for the diagnosis and management of the systematic disease, EurOpEan Ophthalmic rEviEw which might be occult, and may serve as a common link between ophthalmologists and physicians.
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Causes -Differential Diagnosis
Multiple causes can produce either inadequate tear production or abnormal tear film constitution, resulting in excessively fast evaporation or premature destruction of the tear film.
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To classify and categorise DED, DEWS developed a three-part classification, based on aetiology, mechanisms and disease stage, and further distinguished two main categories of dry eye states by cause: aqueous deficiency and the evaporation 1,2 (see Table 1 ).
In both categories, tear film hyperosmolarity and subsequent ocular surface inflammation are thought to lead to the variety of symptoms and signs associated with dry eye, with a common mechanism. The increased osmolality of the tear film stimulates the expression of interleukin-1β (IL-1β), tumour-necrosis factor-α (TNF-α) and matrix metalloproteinase 9 (MMP-9), as already shown in in vivo animal models. These cytokines enhance mitogen-activated protein kinase (MAPK) cascades and subsequently stimulate the production of inflammatory cytokines and MMPs, resulting in DED. 3, 9 Excessive tear evaporation and reduced lacrimal tear secretion results in a vicious cycle of corneal inflammation and ocular dryness, as the aqueous tear pool is reduced.
Any form of lacrimal gland dysfunction or destruction may cause the cycle of reduced tear production, inadequate tear pool, hyperosmolarity of the tear film and inflammation of the ocular surface. The deficiency of aqueous tear production is further subclassified into Sjögren and non-Sjögren syndrome. 3, [11] [12] [13] [14] [15] In Sjögren syndrome, the tear hyposecretion is secondary to an autoimmune infiltration and destruction of the lacrimal gland. This autoimmune exocrinopathy is considered as primary or idiopathic, or secondary -when a systemic connective tissue disease (CTD) is present, e.g. rheumatoid arthritis (most commonly), systemic lupus erythymatosus, scleroderma, primary biliary cirrhosis, polymyositis, dermatomyositis, Hashimoto thyroiditis, interstitial nephritis, Wegener granulomatosis and polyarteritis nodosa. 16, 17 In non-Sjögren syndrome, the deficiency in the tear production is not related to a CTD. The primary type is typically connected to the age-related dry eye, or more rarely to congenital disease e.g. Rilay-Day syndrome and familial dysautonomia.
The secondary type is related to lacrimal gland deficiency due to infiltration of the gland in sarcoidoisis, lymphoma, amyloidosis, haemochromatosis, HIV, graft versus host disease, systemic vitamin A deficiency and lacrimal gland denervation.
Lacrimal gland obstructive disease is caused by trachoma, ocular pemphigoid, erythema multiforme and Stevens Johnson syndrome, ocular burns and post-radiation fibrosis.
Contact lens wearers, people with thyroid disease and people with diabetic neuropathy may suffer from corneal hypoesthesia, impaired sensory drive and subsequently decrease in the reflex tear production.
This reflex sensory aqueous deficiency is additive to any structural and functional alterations that might coexist in the lacrimal gland. 9, 14, 15, [18] [19] [20] Evaporative loss, which causes an unstable tear film and signs and symptoms of DED, without dysfunction of the lacrimal gland tear production, is more commonly related to meibomian gland dysfunction (MGD) or posterior blepharitis. Meibomian glands produce the lipid (outer) layer of the tear film, which protects the tear pool from evaporation. Thus, the dysfunction of meibomian glands causes evaporation of tear film. 3, 11 A significant clinical finding in this common condition is the normal or excessive positive Schrimer I test (more than 15 mm) with low tear break-up time (TBUT) measurement (less than 10 seconds) and a normal tear meniscus with only a small amount of debris, while in Sjögren syndrome aqueous deficiency, the main clinical measurement is the excessive decreased Schrimer test of usually less than 5 mm. 21, 22 In order to establish the diagnosis it is always important to correlate the tear film measurements with clinical signs, e.g. Rose Bengal/Lissamine green stains Marx's line (the mucocutaneous junction of the lid margin) in most eyes with MGD.
Thyroid disease, when involving proptosis or lid retraction, and other ocular conditions with increased intra-palpebral aperture such as floppy eyelid syndrome and lagophthalmos, could also lead to evaporation loss.
Extrinsic causes of evaporative loss are the chronic use of contact lenses, allergic ocular surface disease, topical medications such as beta blockers, miotic agents and preservatives (e.g. benzalkonium chloride), which could decrease the globet cell density and cause instability of the tear film layer. Beta blockers may also cause corneal hypoesthesia, impaired blinking and thus evaporation loss. Finally, vitamin A deficiency causes xerophthalmia, due to disorder of the goblet cells and mucin layer of tear film with the characteristic Bitot spot on the bulbar conjunctiva. [4] [5] [6] [7] [8] 18, 21 For a classification of dry eye on the basis of severity, the Delphi Panel Report was adopted and modified as a third component of the DEWS 3, 11 (see Table 2 ).
Clinical Aproach Risk Factors
The prevalence of DED is higher in the presence of ocular conditions such as blepharitis, MGD and conjunctival disease. In clinical practice, the major risk factors for DED are age, female gender due to menopause hormones and reduced action of androgens (androgens are believed to be trophic for the lacrimal and meibomian glands), diabetes, thyroid disease, systemic medications especially antihistamines, anticholinergics, oestrogens, isotretinoin, selective serotonin receptor antagonists, amiodarone, glaucoma drops (beta blockers and preservatives), decreased corneal sensitivity (e.g. Herpes keratitis) and previous refractive corneal surgery.
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Symptoms
Symptoms of DED vary in accordance to the underlying cause and the onset of the disease. Many patients present with a chronic burning sensation and blurred vision, associated with dryness, while others report tearing, which is a reflex due to the hyperactivation of the sensory sub-basal corneal nerve plexus.
14 By contrast, reflex hyposecretion and a secondary tear film instability due to low blink rate might exist in patients with any kind of corneal neuropathy e.g. diabetes mellitus, thyroid disease and corneal surgery. 9, 14, 15 In general, MGD (evaporative disorder) tends to be worse in the morning, and causes a foreign body sensation and sticky eyes, while the deficiency of tear production tends to be worse in the afternoon, or induces a continual irritation throughout the day. Itchy eyes and especially itchy, swollen eyelids and conjuctival papillae are usually related to ocular allergies.
Still, there is extensive changeability in patients' symptoms and clinical signs, and quite often this is related to the co-existence of several underlying causes of the multifactorial DED. Symptoms of dryness (which gets worse in environment with low humidity or in windy weather conditions), red eyes, foreign body sensation, grittiness, excessive tearing and light sensitivity are all potential complaints. 
Clinical Examination
Clinical examination should follow the recommendation of the DEWS for grading of severity of dry eye.
Examination should note any conjunctival injection/chemosis; also, examination of the lid margin should be performed to rule out meibomian gland disease. 25 Upper eyelid eversion to identify scarring or papillae that might be suggestive of inflammatory or allergic disease (e.g. atopic keratoconjuctivitis, vernal) is essential, especially in chronic disorders. to their potential to cause ocular irritation. 3, 4, 11, 26 Assessment of the tear meniscus -the tear layer between the lower eyelid and the globe, is important in the evaluation of DED and tear film disease. Tear meniscus should be approximately 0.5 mm to 1 mm in height. Reduced tear meniscus lower than 0.2 mm is suggestive for diminished tear production, while increased height suggests obstruction to the nasolacrimal system (punctual obstruction, canalicular stenosis or nasolacrimal duct obstruction). 27, 28 Also, the clinician could perform a dye disappearance test with a drop of 5 μl fluorescein placed in the inferior conjuctival fornix. The amount of fluorescein present in the tear lake is assessed after 5 minutes with a cobalt-blue light, and if most of the dye remains, the lacrimal system is unlikely to be functioning properly. EurOpEan Ophthalmic rEviEw ductules and ductal occlusion are also seen. Secretions from affected patients contain an increase in the concentration of free fatty acids, causing a direct toxic effect to the ocular surface and result in an impaired lipid layer and instability of the tear film. Schirmer test is performed to investigate for tear deficiency DED. A strip of filter paper is inserted on the lateral third of the inferior lid margin, and the wetted paper is measured in millimeters after 5 minutes. Schrimer I, without anaesthetic drops, elicits basic and reflex tearing, and could be considered a valid option for severe DED where results can be reliably repeated. 5, 9 In mild or moderate disease, the measurement is not used alone, but it should be co-analysed with the other ocular surface findings, according to DWES. Measurement below 15 mm is considered moderately reduced, below 10 mm abnormal; if it is below 5 mm, then Sjögren's syndrome should be investigated further. 16, 17, 19 Corneal sensitivity should be measured at the central cornea, to identify Lipid is blotted onto a plastic tape and the change in optical density is used to calculate lipid uptake. Another technique for the assessment of MGD is laser meibometry. Also, the delivery of lipids from the lid reservoir to the preocular tear film can be analysed using interferometry and laser meibometry. 7, 8, 25, 29 However, one of the most significant measurements is the ocular osmolarity, according to a recent guideline of the American Academy of Ophthalmology Preferred Practice Patterns on Dry Eye Syndrome, it is noted that "tear osmolarity has been shown to be a more sensitive method of diagnosing and grading the severity of dry eye compared to corneal and conjunctival staining, TBUT, Schirmer test, and meibomian gland grading". 29, [30] [31] [32] In addition, tear osmolarity showed the lowest variability over time and the highest sensitivity to therapeutic intervention compared with corneal staining, TBUT, Schirmer tests and meibomian gland grading. 33 A new biomarker test was recently approved by the FDA in December 2013 -the InflammaDry (Rapid Pathogen Screening Inc.), which is a rapid in-office test for diagnosing DED. The test, which takes less than 2 minutes to perform, uses tear samples to detect the inflammatory marker MMP-9, which has been shown to be consistently elevated in the tears of patients with DED, due to the inflammation of the ocular surface. 34 Moreover, serology for circulating autoantibodies, including antinuclear antibodies (ANA), anti-Ro/SSA (common in patients with SLE), antiLa/SSB (more specific for primary Sjögren syndrome), anti-neutrophil cytoplasmic antibodies (ANCAs), e.g. c-ANCA for Wegener, rheumatoid factor (RhF), thyroid-stimulating hormone (TSH), serum angiotensinconverting enzyme (ACE) for sarcoidosis, may be indicated according to history and systemic symptoms. Lacrimal gland or salivary gland biopsy may be performed to aid in diagnosing Sjögren syndrome. 16, 17, 35 Finally, impression cytology is a non-invasive technique that can replace conjuctival biopsy in confirmation of diagnosis in DED. One drop of local anaesthetic is instilled into the eye and a millipore cellulose acetate filter paper is applied on the conjunctiva or cornea or both together, straddling the limbus. The paper is allowed to remain in contact with the eye for 
Management of Dry Eye Disease
Management of DED is related to its severity, according to DEWS classification. It is based on reducing the imbalance of tear production and evaporation (by improving tear film volume and stability and reducing tear evaporation and drainage), settling down the ocular surface inflammation and alleviating patient's symptoms. In all cases, control of the underlying systemic disease is needed in order to maintain control of DED (see Table 3 ).
At Level 1, the patient is advised on environmental modifications, e.g. to avoid prolonged activity that reduces blinking, such as prolonged reading or computer use, and to minimise exposure to air conditioning or heating.
Humidifiers might be useful to maintain an acceptable humidity level that will keep the eyes moist and will reduce the evaporation of the tear film. Avoidance of hot, windy, low-humidity and high-altitude environments, as well as smog and smoke, is also advisable. 36, 37 Artificial tears are considered as first-line treatment, as they normalise the tear film volume and also improve vision clarity. They should be used frequently, at least four times a day, to enable stabilisation of the ocular surface. Factors to consider when prescribing artificial tears are the viscosity, the preservatives and the substitutes. Low viscosity drops require more frequent administration, but they will not blur the vision, in contrast to high viscosity drops, which have a prolonged effect but might cause blurred vision. Therefore, viscous paraffin-based ointments might be better administered only at night. Preservative-free drops are always better, as they do not exacerbate the inflammation in DED, but they are more expensive and this cost should be considered as the treatment is chronic. 1, 2, 20 As for the substitutes, hypromellose 0.3 % or polyvinyl alcohol drops are two of the simple lubricant drops that are popular for mild eye dryness.
Carboxymethylcellulose 0.5 % in combination with the osmoprotective compatible osmolyte erythritol and glycerine is a more effective choice in providing cytoprotection and also osmoprotection simultaneously and thus requires less frequent use. This is comparable to the sodium hyaluronate 0.18 %, which is also cytoprotective and seems to have improved ocular surface retention to inflamed eyes, due to a specific binding to the CD44, a transmembrane cell surface adhesion molecule. been shown to improve meibomian gland secretion and improve both signs and symptoms of blepharitis. 39, 40 Tetracyclines e.g. doxycycline 100 mg are used for at least 4 weeks duration as they improve the meibomian gland disease and reduce the MMP-9 activity in tear samples. 41, 42 These measures reduce bacterial-induced changes in the lipid component of the tear film, which in turn reduces evaporative tear loss.
In cases of persisting DED, topical antiflammatories could be used to alleviate symptoms and treat the cycle of ocular inflammation. Shortterm treatment with topical 1 % methylprednisolone not only improves clinical outcome, but a recent study has also demonstrated that it may decrease tear osmolarity and cytokine levels. 43 Cyclosporine 0.05 % is an immunosuppressive agent that has been found to reduce the ocular surface inflammation and improve DED. It is relatively safe but may need up to 6 weeks to have an effect. Combination treatment with topical 1 % methylprednisolone for the first few weeks provides faster symptom relief and improvement of ocular symptoms without serious complications. [43] [44] [45] In more severe DED (stage 3), autologous serum (AS) can be derived from patients' blood and used for controlling the ocular inflammation.
It contains growth factors, fibronectin, immunoglobulins and vitamins, usually at higher concentrations than in tears. In a recent study comparing different concentrations, 50 % AS with sodium hyaluronate was more effective than artificial tears in reducing symptoms, corneal epitheliopathy and promoting fast closure of corneal wounds in non-Sjögren patients, while in Sjögren patients 100 % serum was the more effective choice. 46, 47 Exactly the optimal concentration of AS eye drops is not clearly known in the treatment of severe DED. An important component of AS eye drops which makes the dilution of AS to 20 % necessary is transforming growth factor beta (TGF-β). TGF-β is known to have an anti-proliferative effect and at high concentrations (approximately fivefold more in AS than tears) this molecule may suppress wound healing of the ocular surface epithelia. That is one of the reasons why 20 % dilution was used in a whole of the previous AS studies in the literature. 46, 47 Punctal plugs may be used with caution in severe DED. Silicone or collagen plugs could be used initially for a trial period, and then a permanent punctal occlusion with cautery should be considered.
Reported adverse effects in a systematic review included epiphora (overflow of tears), foreign body sensation, eye irritation and spontaneous plug loss. In cases of severe meibomian gland disease, punctual occlusion should be avoided, as it is likely to exacerbate the symptoms, due to inflammatory factors trapped in the water pool. 48, 49 By contrast, the results of a large prospective study shows that a dietary supplementation with a combination of omega-3 essential fatty acids (EFAs) and antioxidants is an effective treatment for dry eye, which might also be considered in meibomian gland disease. 50 Omega-3 and -6 are EFAs, (polyunsaturated fats). They are precursors of eicosanoids, which are locally acting hormones that mediate the inflammatory processes. The four main groups of eicosanoids are prostaglandins, prostacyclins, thromboxanes and leukotrienes. Omega-3
EFAs include alpha linoleic acid (AA) (flaxseed oil), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omega-6 EFAs include linoleic acid (LA), gamma-linoleic acid (GLA), dihomogamma-linoleic acid (DGLA) and arachidonic acid (AA). 51 Evidence suggests that levels of omega-6 are sufficient in the Western diet, so that supplementation of omega-3 may be all that is required to improve the balance of EFAs and reduce inflammatory processes. 52 Supplementation of omega-3 EFA demonstrates an anti-inflammatory action in the lacrimal gland: it prevents apoptosis of secretory epithelial 
